Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab

Ruzzetti, Manuela; Saraceno, Rosita; Carboni, I; Papoutsaki, Marina; Chimenti, Sergio

doi:10.1111/j.1468-3083.2007.02282.x

Cited by 32 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 Though infliximab has shown clinical efficacy in the above listed cases, Lu et al 11 presented a case unresponsive to combination infliximab and acitretin therapy. Of note, the first case of type III classic juvenile-onset PRP successfully treated with infliximab has recently been reported, 12 and the first two cases of type I PRP treated successfully with combination etanercept and acitretin therapy have emerged. 13,14 The T cell modulator efalizumab has been suggested to improve the disease in a 10-year-old boy unresponsible to multiple common therapies 15 but to exacerbate it in an adult patient.…”

Section: Discussionmentioning

confidence: 98%

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Müller

Gattringer

Zelger

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Müller

Gattringer

Zelger

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Infliximab has been successfully used in psoriasis and in several off-label indications, such as hidradenitis suppurativa, pityriasis rubra pilaris and pyoderma gangrenosum among others 19,20. This anti-TNF-α drug was developed for the treatment of various chronic inflammatory disorders mediated by TNF-α and is approved for ulcerative colitis, adult and pediatric Crohn’s disease, rheumatoid arthritis (RA), and ankylosing spondylitis.…”

Section: Infliximabmentioning

confidence: 99%

Infliximab in the treatment of plaque type psoriasis

Saraceno

Saggini²,

Pietroleonardo³

et al. 2009

CCID

View full text Add to dashboard Cite

Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.

show abstract

“…10,11 Whereas, in the literature there are only two reported cases about the usage of ustekinumab in type I PRP.…”

Section: Case Reportmentioning

confidence: 99%

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris

Stefani

Galluzzo²,

Talamonti³

et al. 2013

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Pityriasis rubra pilaris is a rare, chronic erythematous squamous disorder of unknown etiology. The disease is characterized initially by small follicular papules that coalesce into yellowish pink scaly plaques, palmoplantar keratoderma, diffuse furfuraceous scale of the scalp, and frequent progression to exfoliative erythroderma. Generally it is difficult to discern pityriasis rubra pilaris from other skin conditions but key-clinical features help in the diagnosis such as "islands" of spared skin within generalized erythroderma, follicular keratotic plugs, and an orange hue of the involved skin. Treatment options include topical vitamin D analogues, keratolytics, systemic acitretin, methotrexate, cyclosporine, azathioprine, fumaric acid esters, phototherapy, and anti-TNFα agents. Cases, of pityriasis rubra pilaris, successfully treated with a short-course ustekinumab therapy, have been reported. Main observations:We report a 31-year-old man with pityriasis rubra pilaris, refractory to conventional treatments, successfully treated with ustekinumab monotherapy for over 64 weeks. After failing conventional systemic agents (cyclosporine, aciretin and methotrexate), ustekinumab 45 mg has been prescribed, with the same dosing regimen as in psoriasis. The patient improved dramatically within 4 weeks of the first injection, with markedly less erythema and pruritus. Long-term control of the disease of the disease was achieved (64 weeks of treatment). Conclusion:We report this case in order to show the striking and rapid efficacy of ustekinumab in reducing the signs and symptoms of the disease. Complete remission was achieved after the third injection, but also a long-term control of the disease. The therapy was well-tolerated in our patient and no adverse events occurred.

show abstract

Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab

Cited by 32 publications

References 15 publications

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapy

Infliximab in the treatment of plaque type psoriasis

Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris

Contact Info

Product

Resources

About